FindTrial
Sign In

Group 1: Placebo

DRUG4 trials

Sponsors

Universität Graz, Janssen Research & Development, LLC

Conditions

ColitisCrohn's DiseaseIBDInflammatory Bowel DiseaseNonradiographic Axial Spondylitis, Ankylosingdepression F32

Phase 3

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
CompletedNCT01369342
Janssen Research & Development, LLCColitis, Crohn's Disease, IBD +1
Start: 2011-07-31End: 2014-10-31Updated: 2017-01-06
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
CompletedNCT01369329
Janssen Research & Development, LLCColitis, Crohn's Disease, IBD +1
Start: 2011-07-31End: 2013-07-31Updated: 2016-12-07
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
TerminatedNCT02407223
Janssen Research & Development, LLCNonradiographic Axial Spondylitis, Ankylosing
Start: 2015-07-13End: 2017-09-26Updated: 2019-03-13

Unknown Phase

Placebo effects during the waiting period for psychotherapy in patients with depression
Active, not recruitingDRKS00028118
Universität Grazdepression F32
Start: 2022-03-14Target: 67Updated: 2025-11-24

Related Papers

Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years.
2026-07-10
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
2024-08-0118 citations
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease
Clinical Gastroenterology and Hepatology2023-06-289 citations
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
2023-06-2710 citations
Placebo effects during the waiting period for psychotherapy in patients with depression
Current Psychology2023-01-055 citations
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
2022-09-2129 citations
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A <i>post hoc</i> analysis of the UNITI studies
United European Gastroenterology Journal2021-06-0133 citations
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
Journal of Crohn s and Colitis2021-05-2461 citations
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Inflammatory Bowel Diseases2020-09-23112 citations
Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials
Journal of Crohn s and Colitis2020-09-1122 citations
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease
Gastroenterology2019-07-0465 citations
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Drug Safety2019-02-08114 citations
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
2018-08-29139 citations
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
2018-06-26268 citations
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
2018-02-01188 citations
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal Research2017-01-0123 citations
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
2016-11-011340 citations
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
New England Journal of Medicine2013-08-212650 citations